Projects per year
Personal profile
Interests
Nanomedicine, Antibodies, Antibody-Drug Conjugates (ADCs), cathepsin proteases, cancer, inflammation, infection
Research Statement
Following a primary degree in Biochemistry he undertook a PhD and post doctoral training at Queen’s in molecular enzymology. In 2001, Chris was one of the founding members of QUB spinout company Fusion Antibodies Ltd., before returning to Queen’s in 2003 to take up an academic position. Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Work in his laboratory is funded by agencies such as Medical Research Council, US-Ireland, and various industrial sources such as AstraZeneca and Immunocore. He also held a Royal Society Industrial Fellowship with GSK from 2012-15, and won the Vice Chancellor’s Prize for Innovation in 2015 with his group’s work on developing a novel nanomedicine for the treatment of sepsis and other inflammatory conditions. Chris is a member of the Medical Research Council Developmental Pathway Funding Scheme Panel.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Christopher Scott is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 12 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
R1300CNR: Future Medicines Institute
Scott, C. (PI), Bruce, I. (CoI), Burden, R. (CoI), Burrows, J. (CoI), Collins, B. (CoI), Harrison, T. (CoI), James, J. (CoI), Kennedy, R. (CoI), Lawler, M. (CoI), Longley, D. (CoI), Maguire, S. (CoI), Malinova, D. (CoI), Maule, A. (CoI), McCloskey, K. (CoI), McDade, S. (CoI), Salto-Tellez, M. (CoI), Savage, K. (CoI), Stitt, A. (CoI) & Williams, R. (CoI)
15/10/2024 → …
Project: Research
-
R1365CNR: Development of a Chemoproteomics Centre of Excellence: A Prosperity Partnership for Drug Discovery in Northern Ireland
Scott, C. (PI), Coll, R. (CoI), Collins, B. (CoI), Graham, B. (CoI) & Longley, D. (CoI)
08/11/2023 → …
Project: Research
-
R1589CNR: Dissecting the role of macrophage-derived cysteine cathepsin S in lung adenocarcinoma
Small, D. (PI), Kerr, E. (CoI), Scott, C. (CoI) & Williams, R. (CoI)
06/12/2021 → …
Project: Research
-
-
-
Formulation and evaluation of PVA-based composite hydrogels: physicochemical, leachables, and in vitro immunogenicity studies
Himawan, A., Korelidou, A., Pérez-Moreno, A. M., Paris, J. L., Domínguez-Robles, J., Vora, L. K., Permana, A. D., Larrañeta, E., Graham, R., Scott, C. J. & Donnelly, R. F., 06 Jan 2025, (Early online date) In: Journal of Materials Chemistry B. p. - 15 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021
Greene, M. K., Smyth, P., English, A., McLaughlin, J., Bucholc, M., Bailie, J., McCarroll, J., McDonnell, M., Watt, A., Barnes, G., Lynch, M., Duffin, K., Duffy, G., Lewis, C., James, J., Stitt, A. W., Ford, T., O'Kane, M., Rai, T. S. & Bjourson, A. J. & 4 others, , 30 Jan 2024, In: Heliyon. 10, 2, 11 p., e24184.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Chemical production of cytotoxic bispecific antibodies using the Ugi multicomponent reaction
Vaur, V., Koutsopetras, I., Erb, S., Jackowska, B., Benazza, R., Cahuzac, H., Detappe, A., Hernandez-Alba, O., Cianférani, S., Scott, C. J. & Chaubet, G., 26 Jun 2024, (Early online date) In: ChemBioChem. 8 p., e202400170.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Citations (Scopus)8 Downloads (Pure) -
Comprehensive ocular and systemic safety evaluation of polysialic acid-decorated immune modulating therapeutic nanoparticles (PolySia-NPs) to support entry into first-in-human clinical trials
Krishnan, A., Callanan, D. G., Sendra, V. G., Lad, A., Christian, S., Earla, R., Khanehzar, A., Tolentino, A. J., Vailoces, V. A. S., Greene, M. K., Scott, C. J., Kunimoto, D. Y., Hassan, T. S., Genead, M. A. & Tolentino, M. J., 09 Apr 2024, In: Pharmaceuticals (Basel, Switzerland). 17, 4, 21 p., 481.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)15 Downloads (Pure) -
Development of CD33-targeted dual drug-loaded nanoparticles for the treatment of pediatric acute myeloid leukemia
Carvalho, A. M., Greene, M. K., Smyth, P., Mutch, A., McLaughlin, K. M., Cairns, L. V., Mills, K. I., McCloskey, K. D. & Scott, C. J., 14 Oct 2024, In: Biomacromolecules. 25, 10, p. 6503-6514 12 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile
Activities
-
Medical Research Council (External organisation)
Scott, C. (Advisor)
Jan 2022Activity: Membership types › Membership of peer review panel or committee
-
Robert STRAUBINGER
Scott, C. (Host)
Jan 2022 → Jul 2022Activity: Hosting a visitor types › Hosting an academic visitor
-
Dissecting the role of cathepsin S in dna damage repair deficient tumours.
Gallaher, S. (Speaker), Burden, R. (Advisor), Williams, R. (Advisor) & Scott, C. (Advisor)
Feb 2021Activity: Talk or presentation types › Oral presentation
-
UK Vaccine Taskforce
Scott, C. (Advisor)
2021Activity: Consultancy types › Work on advisory panel to industry or government or non-government organisation
-
Liverpool Institute of Cancer Research
Scott, C. (Advisor)
2021 → …Activity: Consultancy types › Work on advisory panel to industry or government or non-government organisation